Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A 2A adenosine receptors (ARs).
1. A method for treating ischemia reperfusion injury (IRI), comprising: administering to a patient in need thereof a therapeutically effective amount of an agent that inhibits Natural Killer T (NKT) cells, wherein the agent is an anti-CD1 antibody or an anti-NK1.1 antibody.
2. The method of claim 1 , wherein the agent inhibits NKT cells by depleting them.
3. The method of claim 1 , wherein the agent inhibits NKT cells by interfering with them.
4. The method of claim 1 , wherein the antibody is an anti-NK1.1 antibody.
5. The method of claim 4 , wherein the anti-NK1.1 antibody is PK136.
6. The method of claim 1 , wherein the anti-CD1 antibody is an anti-CD1a, anti-CD1b, anti-CD1c, or anti-CD1d antibody.
7. The method of claim 6 , wherein the anti-CD1 antibody is selected from 10H3.9.3 (CD1a), BCD1b3 (CD1b), F10/21A3 (CD1c) and CD1d51 (CD 1d).
8. The method of claim 1 , wherein the injury is selected from heart, kidney, skin, and liver ischemia-reperfusion injury.
9. The method of claim 1 , wherein the IRI is liver IRI.
10. The method of claim 1 , wherein the agent is administered orally, intravenously, intraperitoneally, or transdermally.